Read More The rise of obesity Development, investments, partnerships climb, but safety is key The ability of obesity medications to impact co-morbidities, reducing the symptoms and costs associated with down-the-road disease, has attracted significant attention throughout the biopharma industry
Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine
Then, over 30 years ago, clinicians began to see the value of incretin-based therapy for T2DM, which led to a plethora of clinical trials confirming that GLP-1 receptor agonists are effective in the management of T2DM
Understanding semaglutide plateau management becomes critical at this stage, as the body can develop some tolerance to GLP-1 receptor activation over time